Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-CRM Immunogenicity and Safety in Healthy Subjects 2-18 Years in Taiwan
NCT01410474Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal meningitis, sponsored by Novartis. Started Aug 2011; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT01410474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01410474.